Choice of antibody is critical for specific and sensitive detection of androgen receptor splice variant-7 in circulating tumor cells

Tanzila Khan1,2,3,5, John G. Lock3,4, Yafeng Ma1,2,3,5, David G. Harman6, Paul de Souza1,2,3, Wei Chua1,2,5,7, Bavanthi Balakrishnar7, Kieran F. Scott1,2 & Therese M. Becker1,2,3,5

Androgen receptor variant 7 (AR-V7) is an important biomarker to guide treatment options for castration-resistant prostate cancer (CRPC) patients. Its detectability in circulating tumour cells (CTCs) opens non-invasive diagnostic avenues. While detectable at the transcript level, AR-V7 protein detection in CTCs may add additional information and clinical relevance. The aim of this study was to compare commercially available anti-AR-V7 antibodies and establish reliable AR-V7 immunocytostaining applicable to CTCs from prostate cancer (PCa) patients. We compared seven AR-V7 antibodies by western blotting and immunocytostaining using a set of PCa cell lines with known AR/AR-V7 status. The emerging best antibody was validated for detection of CRPC patient CTCs enriched by negative depletion of leucocytes. The anti-AR-V7 antibody, clone E308L emerged as the best antibody in regard to signal to noise ratio with a specific nuclear signal. Moreover, this antibody detects CRPC CTCs more efficiently compared to an antibody previously shown to detect AR-V7 CTCs. We have determined the best antibody for AR-V7 detection of CTCs, which will open future studies to correlate AR-V7 subcellular localization and potential co-localization with other proteins and cellular structures to patient outcomes.

Abbreviations

aa  Amino acid  
ADT  Androgen deprivation therapy  
AR  Androgen receptor  
AR-V7  Androgen receptor variant 7  
CRPC  Castration-resistant prostate cancer  
CTCs  Circulating tumour cells  
CE3  Cryptic exon E3  
DBD  DNA binding domain  
ddPCR  Droplet digital PCR  
FBS  Fetal Bovine Serum  
AR-FL  Full length AR  
Knime  Konstanz Information Miner  
LBD  Ligand binding domain  
NTD  N-terminal domain  
PVDF  Polyvinyl difluoride  
PCa  Prostate cancer  
TBS-T  Tris-buffered saline with 0.1% Tween 20 detergent

1School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia. 2Medical Oncology, Ingham Institute of Applied Medical Research, Liverpool, NSW 2170, Australia. 3Centre of Circulating Tumour Cells Diagnostics & Research, Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia. 4School of Medical Sciences, University of New South Wales, Sydney, Australia. 5South Western Sydney Clinical School, University of New South Wales, Liverpool Hospital, Liverpool, NSW 2170, Australia. 6School of Science, Western Sydney University, Campbelltown, NSW 2560, Australia. 7Department of Medical Oncology, Liverpool Hospital, Liverpool, NSW 2170, Australia. *email: 19153083@student.westernsydney.edu.au; therese.becker@inghaminstitute.org.au
Aberrant activity of the androgen receptor (AR) is central to prostate cancer development and first line therapy for metastatic prostate cancer is androgen deprivation therapy (ADT) which targets AR signalling\(^2\). However, ADT resistance inevitably occurs, and disease is then referred to as castrate resistant prostate cancer (CRPC).

The expression of altered AR proteins translated from alternative AR splice variants has been proposed as a mechanism of ADT resistance\(^3,4\). Expression of the AR splice variant 7 (AR-V7), is correlated with CRPC and is the most frequently identified disease associated variant. AR-V7 is proposed to be ligand independent and constitutively active as a nuclear transcription factor\(^5,6\).

Splicing of the AR gene including exon 1, 2 and 3 together with a cryptic exon 3E (CE3) results in the AR-V7 transcript (Fig. 1A). The unique cryptic exon has allowed the generation of highly sensitive and specific assays to detect AR-V7 at the mRNA level\(^7^{–}\)\(^10\). Importantly, given the general lack of matching tumor tissue for biomarker analysis at the CRPC stage these methods have been used to successfully detect AR-V7 transcripts from liquid biopsies, such as urine, plasma, exosomes and circulating tumor cells (CTCs) with the most reliable data originating from AR-V7 analysis in CTCs\(^11\). Our recent metaanalysis emphasises the potential of AR-V7 detection in liquid biopsies as clinical biomarker, as it demonstrates significant correlation with patient survival overall and in context of specific treatment\(^1\). The presence of full-length AR (AR-FL) and AR-V7 in CTCs has been investigated at the RNA level in a number of studies and CTC-based AR-V7 was found to correlate with metastatic CRPC and primary resistance to abiraterone and enzalutamide\(^12^{–}\)\(^14\).

The AR-V7 protein has 16 distinctive C-terminal amino acids, encoded by an alternate cryptic exon 3 producing a unique AR-V7 C-terminal protein domain, allowing for generation of specific antibodies. To our knowledge seven antibodies are now commercially available designated to specifically detect the AR-V7 protein and have been raised to C-terminal peptides (Fig. 1A). AR-V7 protein detection opens opportunities for immunohistological analysis, however as outlined above tissue is rarely available for advanced prostate cancer analysis. Again, liquid biopsy derived CTCs lend themselves for immunocytostaining of AR-V7 to add to mRNA information that is readily obtained from these samples. Indeed, Scher et al. reported that information regarding AR-V7 subcellular localization within CTCs may add important information correlating to disease progression and therapy response\(^13,16,17\). This is an important finding as it potentially increases the value of AR-V7 screening as a biomarker in prostate cancer. Additionally, cellular AR-V7 protein analysis may enable future detailed investigations into interactions of AR-V7 with other proteins and nucleic acids to help understanding its CRPC related functions.

Here, using a cohort of well characterised prostate cancer cell lines with known and experimentally validated AR-V7 expression, we thoroughly tested the seven commercially available AR-V7 antibodies for their ability to truly detect AR-V7 by immunoblotting and immunocytostaining. Our findings highlight sensitivity, specificity and cross reactivities of antibodies and point towards an antibody of choice for AR-V7 immunocytostaining of CTCs. The antibody prioritised in this study performed well when employed for detection of CTCs from CRPC patients by immunocytostaining. Our finding is highly relevant to enhance AR-V7 utility to screen patients for therapy decisions or to stratify patients for relevant clinical trials.

Methods

**Cell lines.** 22RV1, LNCaP, VCaP, PC3 and DU145 prostate cancer cell lines are here referred to as 22RV1\(^{(AR-FL)+++/AR-V7+++}\), LNCaP\(^{(AR-FL)+++}/(AR-V7)+++\), VCaP\(^{(AR-FL)+++/AR-V7++}\), PC3\(^{(AR-FL)++}/(AR-V7)+\), DU145\(^{AR/(AR-V7)++}\) according to their published and in this study validated AR-FL and AR-V7 expression\(^8\)\(^–\)\(^26\) and cells were grown in DMEM supplemented with 10% Foetal Bovine Serum (FBS), 2 mM l-Glutamine, 4 mM HEPES or MEM supplemented with 10% FBS, 2 mM l-Glutamine, 4 mM HEPES at 37 °C in 5% CO\(_2\). Cell lines were obtained directly or through Australian distributors (Merck/Sigma-Aldrich, Castle Hill; Invitro, Lane Cove, Australia) of the European Collection of Authenticated Cell Cultures (ECACC) or American Type Culture Collection (ATCC) and tested to be mycoplasma free (Mycoplasma Detection Kit, Lonza, Rockland, USA) and STR authenticated (AGRIF, Melbourne, Australia). Cells were seeded at approximately 30–40% confluency and harvested after 72-h culture for immunoblotting and gene expression analysis.

**Antibodies.** Six rabbit anti-human-AR-V7 antibodies were compared in this study: clone EPR15656 (Abcam, VIC, Australia), clone E308L and “polyclonal antibody” (Cell Signalling, Danvers, MA, USA), clone SN8 (Creative Diagnostic, Shirley, NY, USA), clone DHH-1 (RQ4683, Assay Matrix, VIC, Australia), and clone RM7 (RevMab Biosciences, San Francisco, CA, USA), as well as the mouse anti-human-AR-V7 clone AG10008 (Precision Antibody, Columbia, MD, USA). The available information of antigens used for the anti-AR-V7 antibody generation is shown in Fig. 1A. Additional antibodies used in this study are: mouse anti-human-AR-FL, clone ER179 (Abcam, NSW, Australia), rabbit anti-GAPDH clone 14C10 (Cell Signalling, VIC, Australia), Alexa fluor 488 goat anti-rabbit IgG (H + L) (LOT 1423009) or Alexa fluor 488 goat anti-Mouse (H + L) (LOT 1252783) (Life technologies, Eugene, OR, USA), horseradish peroxidase-labelled donkey anti-Rabbit IgG (1:1000 dilution) (Lot 9526417, GE Healthcare, Buckinghamshire, UK) or sheep anti-mouse IgG, Horseradish Peroxidase linked F(ab’\(^\_\)\(^2\)) fragment (1:1000 dilution) (Lot 312511, Amersham, GE Healthcare, Buckinghamshire, UK) and Alexa fluor 555 Phalloidin (Abcam, NSW, Australia).

**Droplet digital PCR (ddPCR).** In brief, total RNA was extracted with ISOLATE II RNA Mini Kit (Bio-line, London, UK) from approximately 5 × 10\(^6\) cells. Quality and quantity of RNA was tested using a fragment analyser (5200 Fragment Analyzer System, CA, USA). cDNA was synthesised from 1 µg of total RNA per cell using the SensiFAST cDNA Synthesis Kit (Bioline, London, UK). ddPCR to detect AR-V7 and full-length AR (AR-FL) was performed as described previously\(^15\). Quality of RNA was confirmed by conducting GAPDH ddPCR as described previously\(^11\).
Figure 1. AR-V7 specific peptide and antigens for antibody generation. (A) Schematic presentation of the AR-gene encoding full length androgen receptor (AR-FL) and androgen receptor variant 7 (AR-V7) proteins. Amino acid (aa) sequences of cryptic exon (CE) 3 encoded AR-V7 specific domain (V7spec) and a section of DNA binding domain (DBD) shared with AR-FL are displayed and aa sequences representing antigens for antibody generation is indicated for the clones. Antigen information: as published by supplier or provided on request (*: information is considered ambivalent for four peptides, consequently shown aa sequences may not reflect exact antigen peptides, but are based on “informed assumption” that the V7 specific unique 16 aa are part of all peptides and uncertain proportions of the DBD shared with AR-FL as indicated); ???: DBD aa sequences uncertain; NTD: N-terminal domain; LBD: ligand binding domain; N-: N-terminal; -C: C-terminal. (B) Validation of AR-FL and AR-V7 mRNA expression in the indicated cell lines by ddPCR. – no detection; (+/-) low, but detectable; + detection; +++ high levels of AR-V7 or AR-FL copies; (C) Immunoblotting of total protein lysates from the indicated cell lines for AR-V7 (separate gels for each antibody, left), or AR-FL (right) using the indicated antibodies in reference to GAPDH (cropped from probing of the same membrane shown below each plot).
**Western blotting.** Approximately \(1 \times 10^6\) cultured cells were harvested and lysed in RIPA lysis buffer (50 mM Tris–Cl pH 7.5, 150 mM NaCl, 0.5% Triton X-100, 2 mM EDTA, 2 mM EGTA 25 mM NaF; 10% glycerol) containing 1× protease inhibitors (Roche, Basel, Switzerland) for 30 min placed on ice, followed by maximum microfuge centrifugation speed (11,700xg, 4 °C, 20 min) and recovery of supernatant. Protein concentrations were determined using the DC protein assay kit (Bio-Rad Laboratories, Hercules, CA). 30 μg total protein per sample was separated on 4–12% Bis–Tris gels (Invitrogen, Life Technologies) and transferred to Polyvinyl difluoride (PVDF) membrane (Amersham, GE Healthcare, Buckinghamshire, UK). Membranes were incubated with primary antibodies (dilutions see Supp. Table S1) overnight under gentle agitation at 4 °C. After three Tris-buffered saline with 0.1% Tween 20 detergent (TBS-T) washes, membranes were incubated with horseradish peroxidase-conjugated donkey anti-rabbit IgG (1:1000 dilution) or sheep anti-mouse IgG, horseradish peroxidase linked F(ab)\(_2\), fragment (1:1000 dilution) for 1 h at room temperature and again washed three times. Membranes were developed using Western Lightning ™ Plus-ECL Enhanced Luminol Reagent Plus (LOT 275–13,481) and Western Lightning ™ Plus-ECL Oxidizing Reagent Plus (LOT 265–13,481) (PerkinElmer, Waltham, MA, USA) and imaging was performed with an Odyssey imager (LI-Cor Biosciences, Lincoln, NE).

**Immunocytostaining of cell lines and PBMC.** For each cell line approximately 20,000 cells were seeded on sterile, round coverslips in 12-well plates and cultured for 72 h followed by fixation with 3.7% paraformaldehyde for 10 min. In case of PBMC probing cells were cytospun onto superfrost + slides. Cells were permeabilized with 0.2% Triton-X for 10 min and blocked using 10% goat serum in PBS for 30 min. Primary antibodies were diluted in 0.5% FBS in PBS (Supplementary Table S1) and incubated for 1 h. Secondary antibodies conjugated with Alexa fluor 488 goat anti-rabbit IgG (H + L) (1:5000) or Alexa fluor 488 goat anti-mouse (H + L) (1:5000) were diluted in PBS with 0.5% goat serum and incubated 30 min. Cells were stained with Alexa fluor 555 phalloidin for 0.5 h followed by nuclear staining by using 1× Hoechst (Fluxion, San Francisco, CA, USA) in PBS for 10 min. Coverslips were mounted with Pro Long ™ Glass Antifade Mountant (Eugene, OR, USA). Monochrome images were taken with Olympus IX71 microscope (Olympus, Tokyo, Japan) at \(\times 20\) magnification with identical acquisition settings, below any pixel intensity saturation in the brightest cell labelling conditions.

**CTC enrichment and immunocytostaining.** To validate AR-V7 CTC detection six prostate cancer patients with advanced CRPC, likely to yield high CTC counts, were recruited. For each patient, 2 × 9 mL peripheral blood was collected into 2 EDTA vacutubes (Greiner Bio-One) and processed within 24 h. 2 × 9 mL blood was used to isolate CTCs using RosetteSep™ CTC enrichment cocktail containing anti-CD36 (Stemcell Technologies, Victoria, Australia) according to supplier’s instructions. In brief, blood was incubated with antibody cocktail for 10 min and then diluted with 2% FBS in PBS as recommended by manufacturer, transferred to a Sepmate tube containing lymphoprep density gradient medium (Stemcell Technologies, VIC, Australia) and centrifuged at 1200xg for 10 min. The supernatant with cellular layer was recovered and topped up to 50 mL with 2% FBS in PBS and gently mixed. After a 10-min 300xg spin, the supernatant was discarded, and cells were suspended in residual fluid by gentle tapping. Cells were washed once with PBS and spun again (300xg, 10 min), resuspended in 1.5 mL PBS and transferred to a well of a 24-well glass plate (Greiner Bio-One GmbH, Frickenhausen, Germany) coated with 3.5ug of CellTak (FAL354240, InVitro technologies, VIC, Australia) per cm\(^2\). After spinning the cells onto the glass (200 × g, 10 min) immunocytostaining was essentially performed as above including anti-AR-V7 (E308L or EPR15656) staining and probing for CD45 to exclude lymphocytes and Hoechst to secure nucleated cellular identity. All patient CTC samples were stained in parallel to a positive control 22RV1 sample. To identify CTCs the definition CD45−, AR-V7+ and Hoechst positive was used, where AR-V7 positivity was determined by the parallel 22RV1 probing. Typically, weak but clear AR-V7 staining in 22RV1 was around an intensity value of 2000 (AR488 channel, Olympus cellSens Dimension image analysis software). Consequently, events with intensities below 2000 were considered AR-V7 negative (not CTCs) for patient CTC samples. Images in Fig. 4 are displayed using pseudocolors to allow for merging of images from various channels.

**Image analysis and statistics.** Image J (1.53c, National Institute of Health, USA) was used for RGB stacking and merging of immunostaining images from cell lines before doing quantitative image analysis using CellProfiler (Broad Institute, MIT, Massachusetts, USA) an automated image analysis software to measure biological phenotypes in images\(^{21}\). CellProfiler segmented cell data for at least 150 cells per sample (nucleus and cytoplasm) based on staining and extracted data on nucleus, cell body and cytoplasm and AR-V7 intensity were saved in excel to transfer to Konstanz Information Miner (Knime)\(^{22}\). The quantitative data from CellProfiler was used in Knime to compare the intensity of AR-V7 detected by different antibodies as well as cellular localization of AR-V7.

**Ethical approval and consent to participate.** All methods were performed in accordance with the relevant guidelines and regulations and the study was approved by the South Western Sydney Local Health District Human Ethics Committee (HREC/13/LPOOL/158). Written informed consent was obtained from all patients participating in the study.

**Consent for publication.** All authors agree on the submitted version of the manuscript.
Results
For any antibody to be selective for AR-V7, it must recognise a C-terminal peptide epitope corresponding to the 16 amino acid peptide sequence (EKFRGNCCKHLKMTTRP) unique to AR-V7, encoded by the cryptic exon 3. Supplier information regarding the exact antigens used for antibody generation is considered imprecise for five of the seven antibodies tested here. Nevertheless, one can deduce that the entire 16 amino acids or most are part of any antigenic peptide used for antibody generation. Three of the antibodies are known or implied to have antigen peptides additionally containing parts of at least the DNA binding domain (DBD) shared by AR-V7 and AR-FL (Fig. 1A).

To be able to thoroughly compare these antibodies, AR-V7 status of several prostate cancer cell lines was validated. ddPCR confirmed high and detectable AR-V7 in 22RV1 AR+/AR-V7+++ and lower but readily detectable AR-V7 in VCaP AR+/AR-V7+++, while AR-V7 is negative for LNCap AR+/AR-V7−, PC3 AR+/−/AR-V7−, DU145 AR−/AR-V7−, ddPCR also confirmed known AR-FL status for all lines (Fig. 1B).

To test whether all of the anti-AR-V7 antibodies interact with a protein of the expected AR-V7 size of ~80 kDa in our AR-V7 expressing cell lines, or whether the antibodies may cross react with other proteins we first tested the antibodies by immunoblotting of full protein lysates from all cell lines (Fig. 1C). We also included an anti-AR-FL antibody to clarify whether the AR-V7 antibodies identified protein bands of AR-FL size. None of the specific anti-AR-V7 antibodies produced a band considered AR-FL. Interestingly, only the anti-AR-V7 antibody clones E308L, SN8, RM7 and AG1008 produced a distinct band appearing around the expected AR-V7 size for AR-V7 positive 22RV1 AR+/AR-V7+++ and VCaP AR+/AR-V7+++, cells, while not detecting anything above background in AR-V7 negative cell lines in that protein size range. However, there was clearly some cross-reactivity detected for proteins of smaller size. We considered E308L was the “cleanest” antibody with negligible cross-reactivity detected for AR-V7 negative cell lines. SN8, RM7 and especially AG1008 produced strong reaction to proteins of sizes other than 80 kDa in all, including AR-V7 negative cell lines with one band appearing relatively dominant just below the 28 kDa range.

Two anti-AR-V7 antibodies (EPR15656 and DHH-1), while detecting protein bands corresponding to AR-V7 size in 22RV1 AR+/AR-V7+++ and VCaP AR+/AR-V7+++, cells, additionally detected a very strong band in AR-V7 negative PC3 AR+/−/AR-V7− cells, while additional bands across cell lines evidenced further cross-reactivity for these antibodies. The prominent PC3 AR+/−/AR-V7− protein band was just below the expected AR-V7 size. AR-V7 detection with the polyclonal antibody proved to be highly nonspecific. (Fig. 1C). Complete raw data (images of all immunoblots) are provided as Supplementary Fig. S1.

Although deemed very unlikely that PC3 AR+/−/AR-V7− with undetectable AR-V7 transcript express a slightly truncated form of AR-V7, we wished to rule out AR-V7 identity of this band detected close to 80 kDa. Firstly, we conducted protein Blast searches (blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE = Proteins) of the full AR-V7 specific 16 amino acid sequence as well as the sequence from amino acid 580 and 600 (see Fig. 1A) to the C-terminus of AR-V7 against the human protein database (https://www.uniprot.org), which identified only the AR-V7 splice variant and for the 580/600 to C-terminus peptide additionally to AR-V7 the partially homologue AR variant 5 (see ref. 29 for review of AR variants). Additionally, we were able to elute the ~62 kDa PC3 AR+/−/AR-V7− band of interest from a gel to perform mass spectroscopy and the retrieved data confirmed our Blast data with no proteins detected that share homology to AR-V7 or AR-FL in the excised protein band of interest from PC3 AR+/−/AR-V7− cells. Out of interest the same was done for the 28 kDa band as cross reactivities for that size were detected by several anti-AR-V7 antibodies, no AR(-V7) homology was found. The datasets generated for these analyses are available (https://doi.org/10.26183/7d43-e13).

With Western analysis already pointing towards clear specificity differences between the tested antibodies we excluded two antibodies from further analysis, the polyclonal due to lack of specificity for AR-V7 detection sensitivity and specificity by Western analysis, and the mouse monoclonal AG10008. The latter was excluded due to very strong cross-reactivity in all cell lines with a protein band at ~28 kDa compared to specific AR-V7 band intensity and since ultimately, we aim to perform AR-V7 detection by immunocytostaining of CTCs. In our established CTC workflow antibodies of rabbit origin are more easily integrated for technical reasons. Initial immunocytostaining analysis of the five remaining antibodies was performed focusing on the AR-V7-positive cell line, 22RV1 AR+/AR-V7+++ and the AR-V7-negative cell line LNCap AR+/AR-V7−.

Representative immunocytostaining images of all remaining antibodies in the two cell lines used for monochromatic analysis of staining intensity and subcellular localization are shown in Fig. 2. In comparison to “no prior” control staining we analysed intensity of staining, and subcellular localization of staining as specific AR-V7 staining is expected to be predominantly nuclear. Initial subjective visual analysis clearly favours the E308L and SN8 antibodies that show distinct nuclear AR-V7 staining in 22RV1 AR+/AR-V7+++; however SN8 produces what appears to be cross-reactivity with nucleolar structures in the negative control LNCap AR+/AR-V7− cells. EPR15656, DHH-1 and RM7 appear to produce less distinct staining in 22RV1 AR+/AR-V7+++ vs LNCap AR+/AR-V7− cells. Analysing images using unbiased digital image analysis essentially confirmed these observations, presented in Fig. 3 for nuclear intensity. E308L produced the second highest nuclear staining intensity after SN8 in 22RV1 AR+/AR-V7+++ cells, and that corresponded to the second lowest nuclear staining intensity in AR-V7 negative LNCap AR+/AR-V7−. Since the staining in LNCap AR+/AR-V7− can be attributed to unspecific antibody binding, E308L is the antibody with the best signal detection to noise ratio for AR-V7 immunocytostaining.

The goal of the presented antibody comparison was to find the best suited anti-AR-V7 antibody to probe and analyse AR-V7 in CTCs. With E308L emerging as the favourite candidate anti-AR-V7 antibody while EPR15656 was previously published to be used for AR-V7 immunocytostaining in CTCs, a final validation of both antibodies, E308L and EPR15656, was by detection of CTCs isolated from a small number of CRPC patients (to validate antibody staining this pilot study focussed on patients with advanced CRPC only, see Table 1). It is evident that E308L detected prostate cancer patient CTC numbers are consistently higher, indicating higher sensitivity
of E308L CTC detection. Additionally, heterogeneity of AR-V7 expression is apparent as detection efficiencies are between 7–308% higher using E308L (Table 1). Representative CTC detection with both antibodies is shown in Fig. 4. Importantly, using both antibodies on three healthy donor PBMCs, confirmed negligible background staining for residual blood cells with the anti-AR-V7 antibodies in blood cells (Supplementary Fig. S2).

Discussion
Here we compared various antibodies to establish specific detection of AR-V7 by immunocytostaining with ultimate focus to detect AR-V7 positive CTCs from prostate cancer patient bloods. Initially PCa cell lines with known and here confirmed status of AR-V7 expression (Fig. 1B) provided the tools to precisely judge cross-reactivity of antibodies in AR-V7 negative cells while specific staining and its subcellular localization could
be determined in AR-V7 expressing cells. Western analysis helped to determine sensitivity and specificity of antibodies first, since higher cross-reactivity for immunocytostaining is likely mirrored by the appearance of cross-reactive bands in AR-V7 negative cells and for molecular weights other than the ~80 kDa of AR-V7 in positive cells. Indeed the “cleanest” antibody by Western analysis, E308L, in the end also emerged as our favoured antibody for immunocytostaining as well. The other antibody that performed highly for immunocytostaining in AR-V7 positive 22RV1AR+/AR−V7+++ cells, clone SN8, caused however clearly noticeable nuclear staining in AR-V7 negative LNCapAR+/AR−V7− cells, interestingly of nucleolar appearance. This means use of this antibody for CTC detection likely would cause false positive AR-V7 detection in the cellular compartment that has been linked to AR-V7 activity24, affecting potential for “true” biomarker detection.

Figure 3. AR-V7 staining nuclear intensity. Cells (imaged as presented in Fig. 2) were segmented using CellProfiler based on identification of Hoechst as a nuclear marker and Alexa fluor 555 phalloidin as a cell body marker. This permitted selective measurement of AR-V7 labelling intensities in individual whole cells, as well as in nuclear and cytoplasmic compartments, per cell. Here, nuclear AR-V7 staining intensity (average and standard deviation of at least 150 cells per condition) is depicted after normalisation to control values (no primary antibody labelling), allowing comparison of antibody signals in 22RV1AR+/AR−V7+++ and LNCaPAR+/AR−V7− cells. Fluorescence (Y-axis): in arbitrary units.

Table 1. AR-V7 staining CTC detection by antibody in advanced CRPC patients. CTCs were enriched (RosetteSep) and immunocytostained for detection. Nucleated (Hoechst staining) events were included in CTC counts if negative for CD45 and positive for AR-V7 using the indicated anti-AR-V7 antibodies.

| Patient | Age | Clinical notes                                               | CTC counts |
|---------|-----|--------------------------------------------------------------|------------|
|         |     |                                                             | E308L | EPR15656 |
| 1       | 75  | High grade disease, lymph node involvement (PSMA PET)       | 38     | 23     |
| 2       | 78  | Widespread pelvic disease with vesical and rectal fistula    | 29     | 20     |
| 3       | 77  | Widespread bone metastases, on chemotherapy, anemia         | 69     | 64     |
| 4       | 85  | Widespread bone metastases, starting clinical trial (failed standard therapies) | 45     | 5      |
| 5       | 84  | Aggressive soft tissue disease in neck lymph nodes and meningal metastases despite chemotherapy | 173    | 95     |
| 6       | 77  | Metastatic bone disease, Gleason grade 4+5 = 9              | 184    | 45     |

AR-V7 detection in CTCs by immunocytostaining has been reported previously using the ERP15656 antibody20,24. This prompted us to do a direct comparison of CTC detection in parallel patient blood samples with our favourite E308L as well as the ERP15656 antibody. For proof-of-concept, we focused on a small highly advanced CRPC patient cohort (Table 1) to increase likelihood of high CTC numbers. We also used unbiased CTC enrichment using lymphocyte depletions as AR-V7 has been reported more common in EpCAM-negative CTCs25. Interestingly the E308L did not only consistently detect more CTCs in the small cohort of 6 patients (Table 1), but did so marginally to dramatically, which likely reflects heterogeneous AR-V7 protein levels in patient CTCs. More work is needed to verify the extent and heterogeneity of AR-V7 levels in CTCs. So far EPR15656 staining has shown correlation of AR-V7 CTC staining with patient outcome24. Nevertheless, evaluation in larger patient cohorts is needed to clarify if AR-V7 detection in CTCs by immunocytostaining is better suited to predict patient outcome than detection by mRNA, or if indeed a combination of both methods may have benefit. A clear benefit of detecting the AR-V7 protein rather than only mRNA in CTCs is that it opens opportunities to evaluate cell by cell heterogeneity and how AR-V7 expression and sub-cellular localization is related to that of other proteins, which may not only add to our understanding of AR-V7 function but reveal ways of therapeutically targeting it in the future.
Conclusion
Here we evaluated the commercially available antibodies against AR-V7 for utility in immunocytostaining of cell lines with known AR-V7 status and CRPC patient CTCs. The clone E308L emerged as the favoured antibody considering sensitivity and specificity as shown by immunoblotting and signal to noise ratio in immunocyto-staining. With the growing attraction of liquid biopsies in diagnostic settings, identification of the best antibody to detect AR-V7 in CTCs may help to develop a standardised approach for AR-V7 screening in patient CTCs.

Data availability
All data generated in this study are included either in this article or in a supplementary table. Mass Spectroscopy datasets generated and/or analysed during the current study are available in the Western Sydney University ResearchDirect repository, https://doi.org/10.26183/7d43-ze13.

Received: 10 May 2022; Accepted: 8 September 2022
Published online: 28 September 2022

References
1. Khan, T. et al. Prognostic and predictive value of liquid biopsy-derived androgen receptor variant 7 (AR-V7) in prostate cancer: A systematic review and meta-analysis. Front. Oncol. 12, 963 (2022).
2. Lonergan, P. E. & Tindall, D. J. Androgen receptor signaling in prostate cancer development and progression. J. Carcinogen. 10, 20 (2011).
3. Mostaghel, E. A. et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants. Clin. Cancer Res. 17, 5913–5925 (2011).
4. Nadiminty, N. et al. NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: Role of androgen receptor and its variants. Mol. Cancer Ther. 12, 1629–1637 (2013).
5. Cao, B. et al. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget 5, 1646 (2014).
6. Li, Y. et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 73, 483–489 (2013).
7. Antonarakis, E. S. et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J. Clin. Oncol. 35, 2149 (2017).
8. Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. Engl. J. Med. 371, 1028–1038 (2014).
9. Ousten, W. et al. Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur. Urol. 68, 939–945 (2015).
10. Qu, F. et al. Association of AR-V7 and prostate-specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer. Clin. Cancer Res. 23, 726–734 (2017).
11. Nimir, M. et al. Detection of AR-V7 in liquid biopsies of castrate resistant prostate cancer patients: A comparison of AR-V7 analysis in circulating tumor cells, circulating tumor RNA and exosomes. Cells 8, 688 (2019).
12. Steinestel, J. et al. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget 10, 4213–4223. https://doi.org/10.18632/oncotarget.2035 (2019).
13. Armstrong, A. J. et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: The PROPHECY study. J. Clin. Oncol. 37, 1120–1129. https://doi.org/10.1200/JCO.18.01731 (2019).
14. Sharp, A. et al. Androgen receptor splice variant 7 expression emerges with castration resistance in prostate cancer. J. Clin. Invest. 129, 192–208. https://doi.org/10.1172/JCI122819 (2019).
15. Ma, Y. et al. Droplet digital PCR based androgen receptor variant 7 (AR-V7) detection from prostate cancer patient blood biopsies. Int. J. Mol. Sci. 17, 1264 (2016).
16. Armstrong, A. J. et al. Prospective multicenter study of circulating tumor cell AR-V7 and taxane versus hormonal treatment outcomes in metastatic castration-resistant prostate cancer. JCO Precis. Oncol. 4, 1285–1301 (2020).
17. Scher, H. I. et al. Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer. JAMA 34, 1179–1186 (2018).
18. Zhu, Y. et al. Novel junction-specific and quantifiable in situ detection of AR-V7 and its clinical correlates in metastatic castration-resistant prostate cancer. Eur. Urol. 73, 727–735 (2018).
19. Hu, R. et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69, 16–22 (2009).
20. Scher, H. I. et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA 34, 1441–1449 (2016).
21. Carpenter, A. E. et al. Cell profiler: Image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 7, 1–11 (2006).
22. Berthold, M. R. et al. KNIME-the Konstanz information miner: Version 2.0 and beyond. ACM SIGKDD Explor. Newsl. 11, 26–31 (2009).
23. Kanayama, M., Lu, C., Luo, J. & Antonarakis, E. S. Ar splicing variants and resistance to ar targeting agents. Cancers 13, 2563 (2021).
24. Scher, H. I. et al. Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer. Eur. Urol. 71, 874–882 (2017).
25. Gjyrezi, A. et al. Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. Commun. Biol. 4, 785. https://doi.org/10.1038/s42003-021-02321-9 (2021).

Acknowledgements
We wish to thank the patients that consented to participate in the study.

Author contributions
Conceptualisation: T.K., J.L., K.S., T.B.; Experimental/Analysis: T.K., J.L., Y.M., D.H., K.S., T.B.; Patient recruitment: Pd.S., W.C., B.B.; Manuscript drafting: T.K., K.S., T.B.; Manuscript finalisation: all authors.

Funding
The study was funded by the NHMRC Ideas Grant APP1184009.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-20079-w.

Correspondence and requests for materials should be addressed to T.K. or T.M.B.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022